Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-Sisunatovir ADME Study
NCT05873764Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sisunatovir in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Primary endpoints: Time of Maximum Observed Concentration, Maximum Observed Concentration and 6 more. Started May 2022; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05873764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873764.